JP7159307B2 - Ａｔｒキナーゼの複素環式阻害剤 - Google Patents
Ａｔｒキナーゼの複素環式阻害剤 Download PDFInfo
- Publication number
- JP7159307B2 JP7159307B2 JP2020523235A JP2020523235A JP7159307B2 JP 7159307 B2 JP7159307 B2 JP 7159307B2 JP 2020523235 A JP2020523235 A JP 2020523235A JP 2020523235 A JP2020523235 A JP 2020523235A JP 7159307 B2 JP7159307 B2 JP 7159307B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- haloalkyl
- membered heterocycloalkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762531951P | 2017-07-13 | 2017-07-13 | |
| US62/531,951 | 2017-07-13 | ||
| PCT/US2018/042128 WO2019014618A1 (en) | 2017-07-13 | 2018-07-13 | HETEROCYCLIC INHIBITORS OF KINASE ATR |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527174A JP2020527174A (ja) | 2020-09-03 |
| JP2020527174A5 JP2020527174A5 (enExample) | 2021-08-12 |
| JP7159307B2 true JP7159307B2 (ja) | 2022-10-24 |
Family
ID=64998660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523235A Active JP7159307B2 (ja) | 2017-07-13 | 2018-07-13 | Ａｔｒキナーゼの複素環式阻害剤 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10392376B2 (enExample) |
| EP (1) | EP3651768B1 (enExample) |
| JP (1) | JP7159307B2 (enExample) |
| KR (1) | KR102676822B1 (enExample) |
| CN (2) | CN117466884A (enExample) |
| AU (1) | AU2018301696B8 (enExample) |
| CA (1) | CA3069693A1 (enExample) |
| DK (1) | DK3651768T3 (enExample) |
| ES (1) | ES2974334T3 (enExample) |
| FI (1) | FI3651768T3 (enExample) |
| HR (1) | HRP20240368T1 (enExample) |
| HU (1) | HUE066043T2 (enExample) |
| IL (1) | IL271930B (enExample) |
| LT (1) | LT3651768T (enExample) |
| MX (1) | MX2020000386A (enExample) |
| NZ (1) | NZ761374A (enExample) |
| PH (1) | PH12020500072A1 (enExample) |
| PL (1) | PL3651768T3 (enExample) |
| PT (1) | PT3651768T (enExample) |
| RS (1) | RS65466B1 (enExample) |
| SI (1) | SI3651768T1 (enExample) |
| SM (1) | SMT202400106T1 (enExample) |
| WO (1) | WO2019014618A1 (enExample) |
| ZA (1) | ZA202000148B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021518344A (ja) * | 2018-03-16 | 2021-08-02 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | Ａｔｒキナーゼの複素環式阻害剤 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3630116B1 (en) | 2017-05-26 | 2024-05-01 | The Board Of Regents Of The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| US10377591B2 (en) | 2017-07-07 | 2019-08-13 | Zebra Technologies Corporation | Input handling for media processing devices |
| SMT202400106T1 (it) | 2017-07-13 | 2024-05-14 | Univ Texas | Inibitori eterociclici della atr chinasi |
| EP3668839B1 (en) | 2017-08-17 | 2023-04-12 | Board of Regents, The University of Texas System | Heterocyclic inhibitors of atr kinase |
| JP7235338B2 (ja) * | 2017-09-08 | 2023-03-08 | ニューウェーブ・ファーマスーティカル・インコーポレイテッド | Ａｔｒ阻害剤としての置換ピロロピリジン |
| WO2020063751A1 (en) * | 2018-09-27 | 2020-04-02 | Fochon Pharmaceuticals, Ltd. | Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors |
| CN113906026A (zh) * | 2019-06-06 | 2022-01-07 | 北京泰德制药股份有限公司 | 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 |
| CN113121524B (zh) * | 2019-12-31 | 2023-04-25 | 南京创济生物医药有限公司 | 杂环亚砜亚胺化合物及其中间体、制备方法和应用 |
| AU2021282122B2 (en) * | 2020-05-29 | 2023-09-21 | Wuxi Life Fountain Biotech Co., Ltd | Fluoropyrrolopyridine compound and application thereof |
| CA3185491A1 (en) * | 2020-07-03 | 2022-01-06 | Antengene Discovery Limited | Atr inhibitors and uses thereof |
| WO2022171034A1 (zh) * | 2021-02-10 | 2022-08-18 | 江苏先声药业有限公司 | 作为hpk1抑制剂的双环类化合物及其应用 |
| JP2024517906A (ja) * | 2021-05-12 | 2024-04-23 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | スルホンイミドイル含有ａｔｒ阻害剤化合物 |
| CN117500789A (zh) * | 2021-06-17 | 2024-02-02 | 杭州中美华东制药有限公司 | 一种吡啶硼酸酯的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009523161A (ja) | 2006-01-11 | 2009-06-18 | アストラゼネカ アクチボラグ | モルホリノピリミジン誘導体と療法におけるその使用 |
| US20160287604A1 (en) | 2014-08-04 | 2016-10-06 | Bayer Pharma Aktiengesellschaft | 2-(morpholin-4-yl)-1,7-naphthyridines |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001265871A1 (en) * | 2000-04-25 | 2001-11-07 | Actelion Pharmaceuticals Ltd | Substituted sulfonylaminopyrimidines |
| MX2009002046A (es) | 2006-08-24 | 2009-03-06 | Astrazeneca Ab | Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos. |
| CN101563340A (zh) | 2006-09-14 | 2009-10-21 | 阿斯利康(瑞典)有限公司 | 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物 |
| EP2146981A1 (en) | 2007-04-12 | 2010-01-27 | F. Hoffmann-Roche AG | Pharmaceutical compounds |
| WO2008144500A2 (en) | 2007-05-17 | 2008-11-27 | Anadys Pharmaceuticals, Inc. | 1-methyl-benzo[1,2,4]thiadiazine, 1-oxide derivatives |
| ATE554075T1 (de) | 2007-07-09 | 2012-05-15 | Astrazeneca Ab | Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate |
| EP2074118A2 (en) | 2007-07-09 | 2009-07-01 | AstraZeneca AB | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| AU2008273892A1 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| US20110015181A1 (en) | 2008-03-06 | 2011-01-20 | Makoto Ando | Alkylaminopyridine derivative |
| JP2011526931A (ja) | 2008-07-03 | 2011-10-20 | エグゼリクシス， インコーポレイテッド | Ｃｄｋモジュレーター |
| TW201028410A (en) | 2008-12-22 | 2010-08-01 | Astrazeneca Ab | Chemical compounds 610 |
| WO2010120996A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| WO2011106276A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| ES2535116T3 (es) | 2010-03-04 | 2015-05-05 | Cellzome Limited | Derivados de urea sustituida con morfolino como inhibidores de mtor |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| WO2012147890A1 (ja) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
| BR112015012454B1 (pt) | 2012-12-07 | 2022-07-05 | Vertex Pharmaceuticals Incorporated | Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| ES2768678T3 (es) | 2013-12-06 | 2020-06-23 | Vertex Pharma | Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas |
| US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
| ES2777608T3 (es) | 2014-06-05 | 2020-08-05 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo |
| BR112017007708B8 (pt) | 2014-10-13 | 2023-10-24 | Atrin Pharmaceuticals LLC | Composto macrocíclico e composição farmacêutica |
| US10774064B2 (en) | 2016-06-02 | 2020-09-15 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| EP3630116B1 (en) | 2017-05-26 | 2024-05-01 | The Board Of Regents Of The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| SMT202400106T1 (it) | 2017-07-13 | 2024-05-14 | Univ Texas | Inibitori eterociclici della atr chinasi |
| EP3668839B1 (en) | 2017-08-17 | 2023-04-12 | Board of Regents, The University of Texas System | Heterocyclic inhibitors of atr kinase |
| CN112218631B (zh) | 2018-03-16 | 2023-12-22 | 德州大学系统董事会 | Atr激酶的杂环抑制剂 |
-
2018
- 2018-07-13 SM SM20240106T patent/SMT202400106T1/it unknown
- 2018-07-13 LT LTEPPCT/US2018/042128T patent/LT3651768T/lt unknown
- 2018-07-13 DK DK18831104.7T patent/DK3651768T3/da active
- 2018-07-13 MX MX2020000386A patent/MX2020000386A/es unknown
- 2018-07-13 AU AU2018301696A patent/AU2018301696B8/en active Active
- 2018-07-13 EP EP18831104.7A patent/EP3651768B1/en active Active
- 2018-07-13 PT PT188311047T patent/PT3651768T/pt unknown
- 2018-07-13 FI FIEP18831104.7T patent/FI3651768T3/fi active
- 2018-07-13 HU HUE18831104A patent/HUE066043T2/hu unknown
- 2018-07-13 JP JP2020523235A patent/JP7159307B2/ja active Active
- 2018-07-13 HR HRP20240368TT patent/HRP20240368T1/hr unknown
- 2018-07-13 SI SI201831077T patent/SI3651768T1/sl unknown
- 2018-07-13 CN CN202311427557.9A patent/CN117466884A/zh active Pending
- 2018-07-13 IL IL271930A patent/IL271930B/en unknown
- 2018-07-13 NZ NZ761374A patent/NZ761374A/en unknown
- 2018-07-13 PL PL18831104.7T patent/PL3651768T3/pl unknown
- 2018-07-13 CN CN201880051484.9A patent/CN111867590B/zh active Active
- 2018-07-13 KR KR1020207004080A patent/KR102676822B1/ko active Active
- 2018-07-13 ES ES18831104T patent/ES2974334T3/es active Active
- 2018-07-13 CA CA3069693A patent/CA3069693A1/en active Pending
- 2018-07-13 WO PCT/US2018/042128 patent/WO2019014618A1/en not_active Ceased
- 2018-07-13 US US16/035,310 patent/US10392376B2/en active Active
- 2018-07-13 RS RS20240297A patent/RS65466B1/sr unknown
-
2019
- 2019-07-10 US US16/507,851 patent/US10800769B2/en active Active
-
2020
- 2020-01-09 PH PH12020500072A patent/PH12020500072A1/en unknown
- 2020-01-09 ZA ZA2020/00148A patent/ZA202000148B/en unknown
- 2020-09-01 US US17/009,428 patent/US11434233B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009523161A (ja) | 2006-01-11 | 2009-06-18 | アストラゼネカ アクチボラグ | モルホリノピリミジン誘導体と療法におけるその使用 |
| US20160287604A1 (en) | 2014-08-04 | 2016-10-06 | Bayer Pharma Aktiengesellschaft | 2-(morpholin-4-yl)-1,7-naphthyridines |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021518344A (ja) * | 2018-03-16 | 2021-08-02 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | Ａｔｒキナーゼの複素環式阻害剤 |
| JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7159307B2 (ja) | Ａｔｒキナーゼの複素環式阻害剤 | |
| JP7290627B2 (ja) | Ａｔｒキナーゼの複素環式阻害剤 | |
| US10745420B2 (en) | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | |
| JP7341156B2 (ja) | Ａｔｒキナーゼの複素環式阻害剤 | |
| HK40028148B (en) | Heterocyclic inhibitors of atr kinase | |
| HK40028148A (en) | Heterocyclic inhibitors of atr kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210630 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210630 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220616 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220705 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220707 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220913 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221012 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7159307 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |